FTI Consulting Adds EY Global M&A Leader to Transactions Practice
WASHINGTON, Sept. 23, 2024 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Brian Salsberg as […]
Brookfield Raises $2.4 billion for Catalytic Transition Fund Supported by Anchor Commitment from ALTÉRRA
Additional capital raised from CDPQ, GIC, Prudential and Temasek, among others Targeting up to $5 billion, anchored by $1 billion […]
Kodiak Selects Wabash’s Trailers as a Service to Optimize Its Autonomous Fleet
LAFAYETTE, Ind., Sept. 23, 2024 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC), the visionary leader of connected solutions for the transportation, […]
Nordic American Tankers Ltd (NYSE: NAT) – 2024 Annual General Meeting of Shareholders (AGM)
Monday, September 23, 2024 Dear Shareholders and Investors, Please be informed that the date of the Annual General Meeting (AGM) in […]
Brunswick Corporation’s award-winning 2024 Cannes Yachting Festival includes new product announcements and leading market share
CANNES, France, Sept. 23, 2024 (GLOBE NEWSWIRE) — Brunswick Corporation, (NYSE: BC), and many of its industry leading brands, wrapped […]
Caledonia Mining Corporation Plc: Fatal accident at Blanket Mine
ST HELIER, Jersey, Sept. 23, 2024 (GLOBE NEWSWIRE) — It is with regret that Caledonia Mining Corporation Plc (“Caledonia”) (NYSE AMERICAN: […]
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years […]
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in […]
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific […]
Brookfield Corporation Announces Results of Conversion of its Series 40 Preferred Shares
BROOKFIELD, NEWS, Sept. 20, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken […]
